Intravitreal Administration of a Selective HDAC6 Inhibitor Prevents Retinal Damage Progression in the Acute Ocular Toxoplasmosis Model.

ABSTRACT: Ocular toxoplasmosis (OT), caused by Toxoplasma gondii, is the leading cause of retinochoroiditis worldwide, with particularly severe cases in Brazil. The treatment used for OT is the combination of cotrimoxazole and corticosteroids. However, this therapy includes prolonged treatment, resistance to circulating strains, and cytotoxic effects for patients. The intensification of the inflammatory response against T. gondii can exacerbate retinal tissue damage. In this study, the HDAC6 inhibitor Tubastatin A was evaluated by intravitreal injection in the murine ocular toxoplasmosis model. Tubastatin A has presented anti-T. gondii activity and an interesting potential for immunoregulation in the approach to eye disease. The inhibition of HDAC6 interferes with the establishm

SUBMITTER: Araujo-Silva CA 

PROVIDER: S-EPMC12910585 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature